Results from 2 randomized, double-blind, placebo-controlled studies of the novel nk1 receptor antagonist casopitant in patients with major depressive disorder

by Ratti, E., Bellew, K., Bettica, P., Bryson, H., Zamuner, S., Archer, G., Squassante, L., Bye, A., Trist, D., Krishnan, K.R., Fernandes, S.
Published 2014